Go Pro
TSE:CTX

Crescita Therapeutics Q3 2025 Earnings Report

Crescita Therapeutics logo
C$0.79 0.00 (0.00%)
As of 06/4/2026

Crescita Therapeutics EPS Results

Actual EPS
C$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Crescita Therapeutics Revenue Results

Actual Revenue
$5.39 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Crescita Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 4, 2025
Conference Call Time
6:00PM ET

Earnings Documents

Crescita Therapeutics Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Crescita Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Crescita Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescita Therapeutics and other key companies, straight to your email.

About Crescita Therapeutics

Crescita Therapeutics (TSE:CTX) Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.

View Crescita Therapeutics Profile